You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock*

Rodríguez, Alejandro MD, PhD; Mendia, Angel MD; Sirvent, Josep-María MD, PhD; Barcenilla, Fernando MD; de la Torre-Prados, María Victoria MD, PhD; Solé-Violán, Jordi MD, PhD; Rello, Jordi MD, PhD; for the CAPUCI Study Group

Critical Care Medicine:
doi: 10.1097/01.CCM.0000266755.75844.05
Continuing Medical Education Article
Abstract

Objective: To assess whether combination antibiotic therapy improves outcome of severe community-acquired pneumonia in the subset of patients with shock.

Design: Secondary analysis of a prospective observational, cohort study.

Setting: Thirty-three intensive care units (ICUs) in Spain.

Patients: Patients were 529 adults with community-acquired pneumonia requiring ICU admission.

Interventions: None.

Measurement and Main Results: Two hundred and seventy (51%) patients required vasoactive drugs and were categorized as having shock. The effects of combination antibiotic therapy and monotherapy on survival were compared using univariate analysis and a Cox regression model. The adjusted 28-day in-ICU mortality was similar (p = .99) for combination antibiotic therapy and monotherapy in the absence of shock. However, in patients with shock, combination antibiotic therapy was associated with significantly higher adjusted 28-day in-ICU survival (hazard ratio, 1.69; 95% confidence interval, 1.09–2.60; p = .01) in a Cox hazard regression model. Even when monotherapy was appropriate, it achieved a lower 28-day in-ICU survival than an adequate antibiotic combination (hazard ratio, 1.64; 95% confidence interval, 1.01–2.64).

Conclusions: Combination antibiotic therapy does not seem to increase ICU survival in all patients with severe community-acquired pneumonia. However, in the subset of patients with shock, combination antibiotic therapy improves survival rates.

Author Information

Attending Physician, Intensive Care Unit, Joan XXIII University Hospital, Tarragona, Spain (AR); Attending Physician, Intensive Care Unit, Hospital Nuertra Señora de Aranzazu, San Sebastian, Spain (AM); Attending Physician, Department of Intensive Care, Hospital Universitaro de G’Rona, Girona, Spain (J-MS); Director, Infection Control Unit, Attending Physician, Arnau De Vilanova Hospital, Ueida, Spain (FB); Subdirector of Intensive Care Medicine, Hospital Universitario Virgen de la Victoria, Málaga, Associate Professor, Medicine Department, Málaga University, Málaga, Spain (MVT-P); Medical Doctor, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain (JS-V); Chief, Critical Care Department, Joan XXIII University Hospital, Associate Professor of Critical Care, Rovira and Virgili University, Tarragona, Spain (JR).

Supported, in part, by SGR 05/920, FIS 05/2410, FIS 04/1500, and CIBERes 06/06/0036.

Presented, in part, at the ESICM Annual Congress, Barcelona, Spain, September 24–27, 2006.

The authors have not disclosed any potential conflicts of interest.

For information regarding this article, E-mail: jrello.hj23.ics@gencat.net or jordi.rello@urv.cat

© 2007 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins